TaiGen Biotechnology
0 0 0
  • About
      Overview Steering Committee Career Management Team Milestones Board of Directors
      About Us TaiGen is a discovery-based and market-focused pharmaceutical company engaging in the development of novel therapeutics for infectious diseases and other indications with high degree of unmet medical needs.
  • R&D Center
      Pipeline R&D Progress Antibiotic Taigexyn® Influenza Antiviral TG-1000 HCV Antiviral Furaprevir Stem Cell Mobilizer Burixafor Research
      R&D Center TaiGen’s dedicated team of professional scientists perform cutting edge research in drug discovery to advance programs efficiently. Our pipeline of anti-infective & anti-inflammatory programs are the fruits of both internal research as well as in-licensed programs.
  • News News
  • Investors Investors
      Financial Information Material Information Material Information Shareholders' Information Shareholders' Information Corporate Governance Investor FAQs
      Investors Communicating with investors, cultivating long-term investor relations and highlighting corporate’s value.
  • Business & Partnership ESG Contact Us Home 繁中

Devoted to solving challenges to human health

We focus on not only treating disease but also enhancing quality of life.

Dedicated to drug R&D

Focus on discovery of novel drugs to address unmet medical needs

Multiple & flexible business model

Using the Greater China Operation Platform as a springboard to global markets

  • Taigexyn®
  • Antibiotic

  • TG-1000
  • Influenza Antiviral

  • Furaprevir
  • HCV Antiviral

  • Burixafor
  • Stem Cell Mobilizer

February 11, 2025

TaiGen's New Single-Dose Flu Drug Targets Global Markets

December 30, 2024

TaiGen Taigexyn® (Nemonoxacin) Filed NDA in Malaysia

March 31, 2020

R&D

Overcoming antibiotic resistance and other areas of high unmet medical need.

SEE MORE

February 25, 2020

About Us

A discovery-based and market-focused pharmaceutical company with experience in anti-infectives.

SEE MORE

April 9, 2020

Investors

Communicating with investors, cultivating long-term investor relations and highlighting corporate’s value.

SEE MORE

April 9, 2020

ESG

Society provides, so we give back to society. We operate in ways that enhance society and the environment, instead of contributing negatively to them.

SEE MORE

    About Us R&D Center News Investors Business & Partnership ESG Contact Us Privacy Policy 繁中

    © TaiGen Biotechnology Co., Ltd.